Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Author:
Dongho SHIN
1
;
Seung Hwan JEON
;
Junjie PIAO
;
Hyo Jung PARK
;
Wen Jie TIAN
;
Du Geon MOON
;
Sun Tae AHN
;
Kyung-Hwa JEON
;
Guan Qun ZHU
;
Ilbum PARK
;
Hyun-Je PARK
;
Woong Jin BAE
;
Hyuk Jin CHO
;
Sung-Hoo HONG
;
Sae Woong KIM
Author Information
- Publication Type:Original Article
- From:The World Journal of Men's Health 2023;41(3):692-700
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:To evaluated the efficacy and safety of gelatinized Maca (Lepidium meyenii) for eugonadal patients with late onset hypogonadism symptoms (LOH).
Materials and Methods:Participants were instructed to receive 1,000 mg of Maca or placebo, two pills at a time, three times per day for 12 weeks before food intake. To evaluate the efficacy of the drug, Aging Males’ Symptoms scale (AMS), Androgen Deficiency in the Aging Males (ADAM), International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF) questionnaires, serologic tests (total testosterone and free testosterone, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride), body weight, and waist circumference were assessed at 4 and 12 weeks after treatment.
Results:A total of 80 participants were enrolled and randomly assigned to Maca treated group (n=41) or the placebo group (n=39). AMS, IIEF, and IPSS were significantly (p<0.05) improved in Maca treated group than in the placebo group. ADAM positive rate was also significantly (p<0.0001) decreased in Maca treated group.
Conclusions:Maca may be considered an effective and safe treatment for eugonadal patients with late onset hypogonadism symptoms.
